The Effects of Alpha-1 Antitrypsin (AAT) on the Progression of Type 1 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

October 31, 2015

Study Completion Date

May 31, 2016

Conditions
DiabetesType 1 Diabetes
Interventions
DRUG

Alpha 1-Antitrypsin (AAT, Aralast NP)

Eligible subjects will be treated once a week for 8 weeks (8 total treatments).

Trial Locations (1)

80045

Barbara Davis Center for Childhood Diabetes, Aurora

Sponsors
All Listed Sponsors
collaborator

Omni Bio Pharmaceutical, Inc.

INDUSTRY

lead

University of Colorado, Denver

OTHER